- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03939481
Auswirkungen der Behandlung auf die Entwicklung einer Chemotherapie-induzierten peripheren Neuropathie bei Krebspatienten
Eine prospektive beobachtende Kohortenstudie zur Entwicklung eines Vorhersagemodells der Taxan-induzierten peripheren Neuropathie bei Krebspatienten
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Studienübersicht
Status
Bedingungen
- Anatomischer Brustkrebs im Stadium I AJCC v8
- Anatomischer Brustkrebs im Stadium IA AJCC v8
- Anatomischer Brustkrebs im Stadium IB AJCC v8
- Anatomischer Brustkrebs im Stadium II AJCC v8
- Anatomischer Brustkrebs im Stadium IIA AJCC v8
- Anatomischer Brustkrebs im Stadium IIB AJCC v8
- Anatomischer Brustkrebs im Stadium III AJCC v8
- Anatomischer Brustkrebs im Stadium IIIA AJCC v8
- Anatomischer Brustkrebs im Stadium IIIB AJCC v8
- Anatomischer Brustkrebs im Stadium IIIC AJCC v8
- Prognostischer Brustkrebs im Stadium I AJCC v8
- Prognostischer Brustkrebs im Stadium IA AJCC v8
- Prognostischer Brustkrebs im Stadium IB AJCC v8
- Prognostischer Brustkrebs im Stadium II AJCC v8
- Prognostischer Brustkrebs im Stadium IIA AJCC v8
- Prognostischer Brustkrebs im Stadium IIB AJCC v8
- Prognostischer Brustkrebs im Stadium III AJCC v8
- Prognostischer Brustkrebs im Stadium IIIA AJCC v8
- Prognostischer Brustkrebs im Stadium IIIB AJCC v8
- Prognostischer Brustkrebs im Stadium IIIC AJCC v8
- Nicht-kleinzelliges Lungenkarzinom
- Lungenkrebs im Stadium III AJCC v8
- Lungenkrebs im Stadium II AJCC v8
- Lungenkrebs im Stadium IIA AJCC v8
- Lungenkrebs im Stadium IIB AJCC v8
- Lungenkrebs im Stadium IIIA AJCC v8
- Lungenkrebs im Stadium IIIB AJCC v8
- Lungenkrebs im Stadium I AJCC v8
- Lungenkrebs im Stadium IA1 AJCC v8
- Lungenkrebs im Stadium IA2 AJCC v8
- Lungenkrebs im Stadium IA3 AJCC v8
- Lungenkrebs im Stadium IB AJCC v8
- Lungenkrebs im Stadium IIIC AJCC v8
- Eierstockkrebs im Stadium III AJCC v8
- Eierstockkrebs im Stadium IIIA AJCC v8
- Eierstockkrebs im Stadium IIIA1 AJCC v8
- Eierstockkrebs im Stadium IIIA2 AJCC v8
- Eierstockkrebs im Stadium IIIB AJCC v8
- Eierstockkrebs im Stadium IIIC AJCC v8
- Eierstockkrebs im Stadium II AJCC v8
- Eierstockkrebs im Stadium IIA AJCC v8
- Eierstockkrebs im Stadium IIB AJCC v8
- Eierstockkrebs im Stadium I AJCC v8
- Eierstockkrebs im Stadium IA AJCC v8
- Eierstockkrebs im Stadium IB AJCC v8
- Eierstockkrebs im Stadium IC AJCC v8
Intervention / Behandlung
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.
SECONDARY OBJECTIVES:
I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population.
II. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population.
OTHER OBJECTIVES:
I. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN.
OUTLINE:
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Independence, Chile, 8380455
- Instituto Nacional del Cancer
-
-
-
-
-
Bogotá, Kolumbien, 99999
- Instituto Nacional De Cancerologia
-
-
-
-
Tlalpan
-
Mexico City, Tlalpan, Mexiko, 14080
- Instituto Nacional De Cancerologia de Mexico
-
-
-
-
California
-
Antioch, California, Vereinigte Staaten, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Dublin, California, Vereinigte Staaten, 94568
- Kaiser Permanente Dublin
-
Fremont, California, Vereinigte Staaten, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, Vereinigte Staaten, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, Vereinigte Staaten, 94611
- Kaiser Permanente-Oakland
-
Palm Springs, California, Vereinigte Staaten, 92262
- Desert Regional Medical Center
-
San Francisco, California, Vereinigte Staaten, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, Vereinigte Staaten, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, Vereinigte Staaten, 94577
- Kaiser Permanente San Leandro
-
San Rafael, California, Vereinigte Staaten, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, Vereinigte Staaten, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, Vereinigte Staaten, 95403
- Kaiser Permanente-Santa Rosa
-
Vacaville, California, Vereinigte Staaten, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, Vereinigte Staaten, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Vereinigte Staaten, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rocky Mountain Regional VA Medical Center
-
-
Delaware
-
Dover, Delaware, Vereinigte Staaten, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, Vereinigte Staaten, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Fort Myers, Florida, Vereinigte Staaten, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers, Florida, Vereinigte Staaten, 33905
- Florida Gynecologic Oncology
-
Pensacola, Florida, Vereinigte Staaten, 32504
- Sacred Heart Hospital
-
-
Georgia
-
Savannah, Georgia, Vereinigte Staaten, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Vereinigte Staaten, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Vereinigte Staaten, 96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue, Hawaii, Vereinigte Staaten, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Vereinigte Staaten, 96701
- Hawaii Cancer Care - Savio
-
-
Illinois
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Danville, Illinois, Vereinigte Staaten, 61832
- Carle on Vermilion
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Carle Physician Group-Effingham
-
Evergreen Park, Illinois, Vereinigte Staaten, 60805
- Little Company of Mary Hospital
-
Hines, Illinois, Vereinigte Staaten, 60141
- Edward Hines Jr VA Hospital
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Moline, Illinois, Vereinigte Staaten, 61265
- Trinity Medical Center
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Carle Cancer Center
-
Urbana, Illinois, Vereinigte Staaten, 61801
- The Carle Foundation Hospital
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- McFarland Clinic PC - Ames
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52402
- Physicians' Clinic of Iowa PC
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Creston, Iowa, Vereinigte Staaten, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Medical Oncology and Hematology Associates-Laurel
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Vereinigte Staaten, 67601
- HaysMed University of Kansas Health System
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Vereinigte Staaten, 66061
- Olathe Health Cancer Center
-
Salina, Kansas, Vereinigte Staaten, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Vereinigte Staaten, 66606
- University of Kansas Health System Saint Francis Campus
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Associates In Womens Health
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- Flaget Memorial Hospital
-
Lexington, Kentucky, Vereinigte Staaten, 40509
- Saint Joseph Hospital East
-
London, Kentucky, Vereinigte Staaten, 40741
- Saint Joseph London
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Tulane University Health Sciences Center
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- Louisiana State University Health Science Center
-
Shreveport, Louisiana, Vereinigte Staaten, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, Vereinigte Staaten, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, Vereinigte Staaten, 04915
- Waldo County General Hospital
-
Biddeford, Maine, Vereinigte Staaten, 04005
- MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
-
Rockport, Maine, Vereinigte Staaten, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Vereinigte Staaten, 04073
- MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Maine Medical Center- Scarborough Campus
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21204
- Greater Baltimore Medical Center
-
Easton, Maryland, Vereinigte Staaten, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, Vereinigte Staaten, 01805
- Lahey Hospital and Medical Center
-
Winchester, Massachusetts, Vereinigte Staaten, 01890
- Winchester Hospital
-
-
Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Mercy Health Saint Mary's
-
Reed City, Michigan, Vereinigte Staaten, 49677
- Spectrum Health Reed City Hospital
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Munson Medical Center
-
Wyoming, Michigan, Vereinigte Staaten, 49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, Vereinigte Staaten, 55433
- Mercy Hospital
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, Vereinigte Staaten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Vereinigte Staaten, 55432
- Unity Hospital
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Essentia Health Hibbing Clinic
-
Maple Grove, Minnesota, Vereinigte Staaten, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55407
- Abbott-Northwestern Hospital
-
Monticello, Minnesota, Vereinigte Staaten, 55362
- Monticello Cancer Center
-
Robbinsdale, Minnesota, Vereinigte Staaten, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Vereinigte Staaten, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Essentia Health Sandstone
-
Stillwater, Minnesota, Vereinigte Staaten, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Essentia Health Virginia Clinic
-
Willmar, Minnesota, Vereinigte Staaten, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Vereinigte Staaten, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Vereinigte Staaten, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Rolla, Missouri, Vereinigte Staaten, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Springfield, Missouri, Vereinigte Staaten, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Vereinigte Staaten, 63131
- Missouri Baptist Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Vereinigte Staaten, 68803
- CHI Health Saint Francis
-
-
New Hampshire
-
Nashua, New Hampshire, Vereinigte Staaten, 03060
- Saint Joseph Hospital
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
North Carolina
-
Asheboro, North Carolina, Vereinigte Staaten, 27203
- Randolph Hospital
-
Asheville, North Carolina, Vereinigte Staaten, 28803
- AdventHealth Infusion Center Asheville
-
Burlington, North Carolina, Vereinigte Staaten, 27215
- Cone Health Cancer Center at Alamance Regional
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clyde, North Carolina, Vereinigte Staaten, 28721
- AdventHealth Infusion Center Haywood
-
Gastonia, North Carolina, Vereinigte Staaten, 28054
- CaroMont Regional Medical Center
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Greensboro, North Carolina, Vereinigte Staaten, 27403
- Cone Health Cancer Center
-
Hendersonville, North Carolina, Vereinigte Staaten, 28792
- AdventHealth Hendersonville
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
New Bern, North Carolina, Vereinigte Staaten, 28561
- CarolinaEast Medical Center
-
Pinehurst, North Carolina, Vereinigte Staaten, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Rocky Mount, North Carolina, Vereinigte Staaten, 27804
- Nash General Hospital
-
Supply, North Carolina, Vereinigte Staaten, 28462
- NHRMC Radiation Oncology - Supply
-
Wilmington, North Carolina, Vereinigte Staaten, 28401
- New Hanover Regional Medical Center/Zimmer Cancer Center
-
-
North Dakota
-
Minot, North Dakota, Vereinigte Staaten, 58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44307
- Cleveland Clinic Akron General
-
Cincinnati, Ohio, Vereinigte Staaten, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, Vereinigte Staaten, 19460
- Phoenixville Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Vereinigte Staaten, 02886
- Kent Hospital
-
-
South Carolina
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- AnMed Health Cancer Center
-
Bluffton, South Carolina, Vereinigte Staaten, 29910
- Saint Joseph's/Candler - Bluffton Campus
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Florence, South Carolina, Vereinigte Staaten, 29506
- McLeod Regional Medical Center
-
Gaffney, South Carolina, Vereinigte Staaten, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Vereinigte Staaten, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, Vereinigte Staaten, 29926-3827
- South Carolina Cancer Specialists PC
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Vereinigte Staaten, 29379
- MGC Hematology Oncology-Union
-
-
Tennessee
-
Cookeville, Tennessee, Vereinigte Staaten, 38501
- Cookeville Regional Medical Center
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Ballad Health Cancer Care - Kingsport
-
-
Texas
-
Lubbock, Texas, Vereinigte Staaten, 79415
- UMC Cancer Center / UMC Health System
-
Lubbock, Texas, Vereinigte Staaten, 79430
- Texas Tech University Health Sciences Center-Lubbock
-
-
Virginia
-
Bristol, Virginia, Vereinigte Staaten, 24201
- Wellmont Medical Associates-Bristol
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia Cancer Center
-
Mechanicsville, Virginia, Vereinigte Staaten, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, Vereinigte Staaten, 23114
- Bon Secours Saint Francis Medical Center
-
Richmond, Virginia, Vereinigte Staaten, 23226
- Bon Secours Saint Mary's Hospital
-
-
Washington
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Vereinigte Staaten, 98368
- Jefferson Healthcare
-
-
Wisconsin
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Duluth Clinic Ashland
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Cancer Center of Western Wisconsin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Participants with stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer
Beschreibung
Inclusion Criteria:
-
Patients must have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer based on clinical or pathologic evaluation. Patients with Stage IV disease are not eligible.
-
Patients must be planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens (docetaxel chemotherapy regimens for treatment of breast or ovarian cancer, or paclitaxel chemotherapy regimen for treatment of breast, non-small cell lung, or ovarian cancer) within 14 days after registration. (Note that docetaxel or paclitaxel may be administered with a non-neurotoxic chemotherapy, such as cyclophosphamide, and/or biologic agent, such as trastuzumab, and/or carboplatin. Additionally, nab-paclitaxel may not be substituted for paclitaxel for purposes of this study.)
-
Patients who will receive treatment in the setting of any other clinical trial are eligible as long as it is one of the study-approved regimens. Patients may receive additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study.
-
Patients must not have received a taxane (paclitaxel, docetaxel, or protein-bound paclitaxel), platinum (cisplatin, carboplatin, or oxaliplatin), vinca alkaloid (vinblastine, vincristine, or vinorelbine), or bortezomib-based chemotherapy regimen prior to registration. (Note that while patients must not have received carboplatin in the past, patients may receive a carboplatin-containing regimen after registration as part of the docetaxel or paclitaxel regimen.)
-
Patients who can complete Patient-Reported Outcome (PRO) instruments in English or Spanish must:
- Agree to complete PROs at all scheduled assessments
- Complete the baseline PRO forms prior to registration
-
Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson?s disease.
-
Patients must agree to submit required specimens for defined translational medicine.
-
Patients must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With patient?s consent, specimens must be submitted.
-
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
-
As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Observational (non-study chemo, questionnaire, assessments)
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52. |
Given chemotherapy regimen
Andere Namen:
Functional and sensory clinician assessments Patient and physician reported responses |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With Development of Peripheral Neuropathy
Zeitfenster: Up to 24 weeks
|
Will be measured as an absolute increase of >= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. Will be collected before or at the 24-week assessment.. |
Up to 24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
CIPN Symptoms
Zeitfenster: Up to 52 weeks
|
Patients experiencing a treatment change attributed to CIPN symptoms |
Up to 52 weeks
|
|
Dose Changes
Zeitfenster: Up to 52 weeks
|
Dose reductions, delays, and discontinuations of treatment (prior to completing the original treatment plan) |
Up to 52 weeks
|
|
Health-related Quality of Life
Zeitfenster: Up to 52 weeks
|
Assessed using the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29). The PROMIS-29 is a well validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning. |
Up to 52 weeks
|
|
Visual Analog Toxicity Score
Zeitfenster: Up to 52 weeks
|
Assessed using the Visual Analog Toxicity Score. The Visual Analog Toxicity Score is a single question asking the physician to rate how the physician feels the patient's disease and treatment affects their daily life on a scale from 0 (no symptoms and no effect on life) to 10 (severe effects of treatment and patient would rather be dead). |
Up to 52 weeks
|
|
Patient Reported Symptom
Zeitfenster: Up to 52 weeks
|
Assessed using the Patient Reported Symptom Burden Score. The Patient Reported Symptom Score at baseline contains one question to assess how cancer symptoms affect the patient's life (scale 0 [no burden at all] to 10 [a great burden]). At follow-up, the Symptom Burden Score contains five questions: 1) to assess burden of side effects of cancer treatment on life (scale 0 [no burden at all] to 10 [a great burden]), 2) to assess severity of side effects from cancer treatment (scale 0 [no side effects]) to 10 [side effects extremely severe and unbearable]), 3) to assess tolerability of side effects for set time periods (yes/no), 4) to assess level at which treatment would be considered intolerable (scale 0 [side effects not severe at all] to 10 [side effects extremely severe and unbearable]), and 5) to assess the burden of cancer symptoms and treatment symptoms (scale 0 [no burden at all] to 10 [a great burden]). |
Up to 52 weeks
|
|
Leisure-time Exercise Habits
Zeitfenster: Up to 52 weeks
|
Assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). The GSLTPAQ is a brief 4 item self-administered questionnaire of usual leisure-time exercise habits over a typical 7-day period. The Leisure Score Index (LSI) is calculated based on the first 3 questions. The LSI scores can be used to classify respondents into active (LSI > 24) and insufficiently active (LSI < 23) categories. |
Up to 52 weeks
|
|
Patient-Reported Outcomes
Zeitfenster: Up to 52 weeks
|
Assessed using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE [CTCAE Version 5.0]). PRO-CTCAE assesses 78 adverse events by self-report with 124 items. Each item uses a plain language term for the adverse event, the attribute of interest, and the standard recall period of "the past 7 days". |
Up to 52 weeks
|
|
National Cancer Institute-Common Terminology Criteria for Adverse Events
Zeitfenster: Up to 52 weeks
|
The NCI-CTCAE is a subjective method to evaluate CIPN performed by a healthcare professional. The treating physician will grade the subject's dysesthesia, paresthesia, neuralgia, peripheral sensory neuropathy, and peripheral motor neuropathy on a scale of 0 to 5 depending on the severity. The advantage of the NCI-CTCAE is that the assessment is quick and easy for providers to perform, (8) but it is limited by the subjectivity of interpretation, lack of detail about location, type, and severity of impairment, and narrow scoring range. Participants will only be graded for the event types listed above, so these will only be reported as an outcome measure, and will not appear in the adverse events section of this report. |
Up to 52 weeks
|
|
Assess Incidence of CIPN
Zeitfenster: Up to 52 weeks
|
Assessed using European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 (CIPN-20). The EORTC QLQ-CIPN20 is a 20-item questionnaire that evaluates CIPN using 3 subscales that assess sensory (9 items), motor (8 items), and autonomic (3 items) symptoms and functioning with each item measured on a 1-4 scale (1, not at all; 4, very much). The sensory subscale raw scores range from 1 to 36. The CIPN-20 subscale raw scores are linearly converted to a 0-100 scale such that a high score corresponds to a worse condition or more symptoms. |
Up to 52 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Meghna S Trivedi, SWOG Cancer Research Network
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Erkrankungen des endokrinen Systems
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Erkrankungen der Atemwege
- Genitalerkrankungen, weiblich
- Lungenkrankheit
- Neoplasmen der endokrinen Drüse
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Eierstockerkrankungen
- Adnexerkrankungen
- Genitale Neubildungen, weiblich
- Gonadenstörungen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Eierstocktumoren
- Karzinom, nicht-kleinzellige Lunge
- Therapeutika
- Arzneimitteltherapie
Andere Studien-ID-Nummern
- S1714
- UG1CA189974 (US NIH Stipendium/Vertrag)
- S1714 (Andere Kennung: CTEP)
- NCI-2018-01568 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- SWOG-S1714 (Andere Kennung: DCP)
- S1714 (Andere Kennung: SWOG)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .